Jak2 mutation
Reading File
Finding Sources
Searching PubMed
"JAK2 mutation"
Searching the Web
JAK2 mutation myeloproliferative neoplasms diagnosis current reliable source
JAK2 mutation is an acquired genetic change in blood-forming cells. The most common type is JAK2 V617F. It keeps JAK2 signaling switched on, which can cause overproduction of blood cells.
It is strongly associated with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs):
| Condition | Approximate frequency of JAK2 mutation |
|---|---|
| Polycythemia vera (PV) | >95% |
| Essential thrombocythemia (ET) | 50%-60% |
| Primary myelofibrosis (PMF) | 50%-60% |
In suspected PV with a negative V617F test, testing for JAK2 exon 12 variants is often considered. SEER's JAK2 reference summarizes its diagnostic use.
What a positive result means
- It supports a possible MPN, especially if hemoglobin/hematocrit, platelets, or white blood cells are persistently elevated.
- It does not by itself establish a diagnosis. Diagnosis also uses blood counts, erythropoietin level in possible PV, clinical history, and often bone marrow findings.
- A low-level JAK2 mutation can sometimes represent clonal hematopoiesis without overt MPN, but it still warrants clinical assessment because it may be associated with thrombosis risk. A recent study reported mechanisms linking JAK2 V617F clonal hematopoiesis to arterial thrombosis (PMID 38142422).
Symptoms that may prompt testing: unexplained high red cells or platelets, headaches, dizziness, itching after a warm bath, erythromelalgia (burning red hands/feet), enlarged spleen, or an unexplained blood clot, particularly at an unusual site.
If you have a lab result, share the exact wording, such as V617F vs exon 12, the variant allele frequency (VAF), and your CBC values. A hematologist should interpret it in context, especially if there is a history of clotting, marked symptoms, or abnormal blood counts.
This is a shared conversation. Sign in to Orris to start your own chat.